Has aducanumab’s approval been terminated by the US FDA?

The U.S. Food and Drug Administration (FDA) approved the use of aducanumab (Aducanumab) in 20216 months. However, the approval was conditional, which triggered widespread controversy and concern. The decision has sparked mixed opinions among the medical community and the public, as the aducanumab approval process involves complex scientific and ethical issues.

Conditional approval:

The FDA's approval is conditional, meaning it requires the pharmaceutical company to conduct further studies to verify aducanumab's clinical effects. Specifically, the FDA requires pharmaceutical companies to conduct follow-up studies to verify whether the drugs can improve patients' cognitive function and daily living abilities. This also includes an assessment of the patient's long-term effects of treatment.

Controversies and concerns:

The approval of aducanumab has sparked controversy and concern for reasons including:

1.Insufficient evidence: Some experts and researchers believe that the existing clinical trial data are not sufficient to prove the actual effect of aducanumab. Some clinical trials have shown positive results, while others have not.

2.High cost: The cost of treatment with aducanumab can be very high, raising concerns about its accessibility and cost-effectiveness. This has many patients and health insurance companies concerned about the financial burden of the drug.

3.Potential side effects: The use of aducanumab may cause some adverse reactions, including skin reactions, headache, nausea and vomiting, and potential risk of cerebral hemorrhage.

It is important to note that the approval status of a drug may change over time. Therefore, it is recommended to check the latestFDANotice or consult your healthcare professional for the latest information about aducanumab. In addition, the scientific and medical communities are still conducting research and evaluation to more fully understand the potential benefits and risks of this new treatment. Taken together, the approval of aducanumab is still a controversial issue, and its long-term efficacy and actual effects still require further verification and research.